Last reviewed · How we verify
MCS-2
MCS-2 is a small molecule that targets the SGLT2 receptor.
MCS-2 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | MCS-2 |
|---|---|
| Also known as | MUS |
| Sponsor | Health Ever Bio-Tech Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the SGLT2 receptor, MCS-2 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. Its exact mechanism of action is still being studied in clinical trials.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (PHASE3)
- Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (PHASE3)
- MCS in the Treatment of Lower Urinary Tract Symptoms (PHASE2, PHASE3)
- Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c) (PHASE3)
- Pharmacokinetics of MCS in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |